Odonate Therapeutics Inc. (ODT)

27.94
0.56 2.00
NASDAQ : Health Technology
Prev Close 28.50
Open 28.48
Day Low/High 27.60 / 28.81
52 Wk Low/High 11.54 / 43.75
Volume 119.63K
Avg Volume 114.80K
Exchange NASDAQ
Shares Outstanding 32.19M
Market Cap 917.44M
EPS -3.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Odonate Therapeutics Announces Public Offering Of Shares Of Common Stock

Odonate Therapeutics Announces Public Offering Of Shares Of Common Stock

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has commenced an underwritten public offering...

Independent Data Monitoring Committee (IDMC) Recommends CONTESSA Continue With No Modifications Following Planned Interim Efficacy Futility Analysis

Independent Data Monitoring Committee (IDMC) Recommends CONTESSA Continue With No Modifications Following Planned Interim Efficacy Futility Analysis

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that the IDMC for CONTESSA, Odonate's Phase 3 study...

Odonate Therapeutics To Present At The Jefferies 2019 Global Healthcare Conference

Odonate Therapeutics To Present At The Jefferies 2019 Global Healthcare Conference

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, will present at the Jefferies 2019 Global Healthcare Conference on...

Odonate Therapeutics Becomes Oversold (ODT)

Odonate Therapeutics Becomes Oversold (ODT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Odonate Therapeutics Announces Financial Results For The Three Months Ended March 31, 2019

Odonate Therapeutics Announces Financial Results For The Three Months Ended March 31, 2019

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31,...

Tesetaxel Brain Concentrations Exceeded Concentrations Required For Tumor Killing For Sustained Period Of Time In Preclinical Testing

Tesetaxel Brain Concentrations Exceeded Concentrations Required For Tumor Killing For Sustained Period Of Time In Preclinical Testing

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today presented results of preclinical studies of tesetaxel, Odonate's...

Odonate Therapeutics Initiates CONTESSA TRIO

Odonate Therapeutics Initiates CONTESSA TRIO

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the initiation of CONTESSA TRIO, a multi-cohort,...

Odonate Therapeutics To Present At The Cowen And Company 39th Annual Health Care Conference

Odonate Therapeutics To Present At The Cowen And Company 39th Annual Health Care Conference

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, will present at the Cowen and Company 39th Annual Health Care...

Odonate Therapeutics Announces Initiation Of CONTESSA 2, A Phase 2 Study Of Tesetaxel In Patients With Locally Advanced Or Metastatic Breast Cancer Who Have Not Previously Received A Taxane

Odonate Therapeutics Announces Initiation Of CONTESSA 2, A Phase 2 Study Of Tesetaxel In Patients With Locally Advanced Or Metastatic Breast Cancer Who Have Not Previously Received A Taxane

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has initiated CONTESSA 2, a multinational,...

Odonate Therapeutics Announces Presentation At The American Association For Cancer Research (AACR) Annual Meeting 2019

Odonate Therapeutics Announces Presentation At The American Association For Cancer Research (AACR) Annual Meeting 2019

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the acceptance for presentation at the American...

Odonate Therapeutics Announces Financial Results For The Three And Twelve Months Ended December 31, 2018

Odonate Therapeutics Announces Financial Results For The Three And Twelve Months Ended December 31, 2018

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months...

Odonate Therapeutics Becomes Oversold (ODT)

Odonate Therapeutics Becomes Oversold (ODT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Odonate Therapeutics Announces Financial Results For The Three And Nine Months Ended September 30, 2018

Odonate Therapeutics Announces Financial Results For The Three And Nine Months Ended September 30, 2018

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended...

Odonate Therapeutics Announces Financial Results For The Three And Six Months Ended June 30, 2018

Odonate Therapeutics Announces Financial Results For The Three And Six Months Ended June 30, 2018

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended...

Odonate Therapeutics Becomes Oversold (ODT)

Odonate Therapeutics Becomes Oversold (ODT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Odonate Therapeutics Announces Presentations At The 2018 American Society Of Clinical Oncology (ASCO) Annual Meeting

Odonate Therapeutics Announces Presentations At The 2018 American Society Of Clinical Oncology (ASCO) Annual Meeting

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that there will be two poster presentations on...

Odonate Therapeutics Announces Financial Results For The Three Months Ended March 31, 2018

Odonate Therapeutics Announces Financial Results For The Three Months Ended March 31, 2018

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31,...

Odonate Therapeutics Announces Financial Results For The Three And Twelve Months Ended December 31, 2017

Odonate Therapeutics Announces Financial Results For The Three And Twelve Months Ended December 31, 2017

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for...

Odonate Therapeutics Announces Initiation Of CONTESSA, A Phase 3 Study Of Tesetaxel In Patients With Locally Advanced Or Metastatic Breast Cancer

Odonate Therapeutics Announces Initiation Of CONTESSA, A Phase 3 Study Of Tesetaxel In Patients With Locally Advanced Or Metastatic Breast Cancer

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has initiated...

Odonate Therapeutics Announces Closing Of Initial Public Offering

Odonate Therapeutics Announces Closing Of Initial Public Offering

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the closing of its...